Biotech Values

[DewDiligence]

Albuferon quiz:

HGSI conducted market research to assess what kind of market share is potentially achievable within the overall interferon market for treatment of HCV. They found that, if Albuferon is merely as good as Pegasys in SVR rate and tolerability, then the advantage of biweekly Albuferon dosing vs weekly Pegasys dosing could allow Albuferon to capture a 50% market share.

In addition, HGSI’s market research quantified how much incremental market share could be achieved if:

a) Albuferon dosed biweekly were to show a better SVR rate than Pegasys;

b) Albuferon dosed biweekly were to show better tolerability than Pegasys; or

c) Albuferon dosed monthly were to show comparable SVR and tolerability to Pegasys.

--
Rank a), b), and c), above, in order of importance from most to least.